TFS
TCRT icon

TrustCore Financial Services’s Alaunos Therapeutics TCRT Stock Holding History

TrustCore Financial Services’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$162 Hold
2
– – ﹤0.01% 1003
2022
Q3 		$0 Hold
2
– – ﹤0.01% 1168
2022
Q2 		$0 Hold
2
– – ﹤0.01% 1126
2022
Q1 		$0 Hold
2
– – ﹤0.01% 1103
2021
Q4 		$0 Buy
+2
New +$440 ﹤0.01% 1046

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
MP
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Addison Capital Conshohocken, Pennsylvania $610M AUM 17.84% 1-Year Est. Return
SGCA
Steel Grove Capital Advisors Memphis, Tennessee $1.07B AUM 26.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

TrustCore Financial Services's TCRT Position: Q4 2022 in Review

TrustCore Financial Services held its Alaunos Therapeutics (TCRT) position steady in Q4 2022 at 2 shares worth $162. The position accounts for ﹤0.01% of the portfolio, ranked #1003.

TrustCore Financial Services first reported a position in TCRT in Q4 2021 and has held it in 5 quarters since. 121 funds tracked by Wall St. Rank hold TCRT as of Q4 2022.

  • TrustCore Financial Services held 2 shares of Alaunos Therapeutics worth $162 as of Q4 2022.
  • TrustCore Financial Services left its Alaunos Therapeutics share count unchanged in Q4 2022.
  • Alaunos Therapeutics made up ﹤0.01% of TrustCore Financial Services's portfolio in Q4 2022, its #1003 holding.
  • TrustCore Financial Services first reported a position in Alaunos Therapeutics in Q4 2021 and has held it in 5 quarters since.
  • 121 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2022.

Based on TrustCore Financial Services's 13F filing for Q4 2022, filed 13 Feb 2023.